Healthcare
Live Price
Offline$2.55
+11.35% today
1Y Change
+111.58%
Window
Jun 30, 2025 → Jun 18, 2026
Coverage: 244 bars · Jun 30, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lexicon Pharmaceuticals, Inc. (LXRX) is a Healthcare stock with a market cap of $690.00M and listed on NASDAQ. The stock last traded around $2.55 and up 111.6% across the available one-year price window (Jun 30, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +60.2%, EPS growth of +77.8%, a dividend yield of 0.0%. What stands out right now is revenue +60.2%, EPS +77.8%, free cash flow +62.3% with operating margin -98.2% and ROIC -28.7%. Valuation already assumes a fairly strong business story at price/sales 13.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines LXRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
LXRX is 90.72 pts ahead over the shared 1Y window.
LXRX had 24.96 pts deeper max drawdown than SPY.
LXRX beat SPY in 2 of 2 calendar years shown and trailed in 0.
LXRX
+111.58%
Normalized return
SPY
+20.86%
S&P 500
Excess Return
+90.72 pts
Relative to SPY
LXRX Max Drawdown
-34.09%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for LXRX and SPY.
| Year | LXRX | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +76.32% | +6.71% | +69.61 pts | LXRX |
| 2025 | +21.05% | +11.19% | +9.86 pts | LXRX |
Unable to load analyst forecasts.
Timed out loading forecasts for LXRX
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.